Primary nonresponse to infliximab in patients with ulcerative colitis (UC) is common. However, there are currently no effective biomarkers for this prediction. This study aimed to identify potential predictors for precision anti-tumor necrosis factor-alpha treatment in patients with UC. Four GPL570 datasets (GSE14580, GSE12251, GSE23597, and GSE16879) were included in this study. Sixty-nine differentially expressed genes (DEGs) were identified, while 67 were up-regulated and two were down-regulated by comparing the gene expression in response samples...

Additional file 2. Differentially expressed gene data.

Additional file 3. Differentially expressed protein data.

Additional file 3.

Additional file 2: Dataset S1. Comparative overall mitogenomic architecture features of the Acanthocephala. Dataset S2. Comparative features of individual genes in mitogenomes of the Acanthocephala.

Additional file 2: Table S2. The PgMYB protein sequences for phylogenetic analysis.

Additional file 11: Drugs with significant differences in IC50 values between high-risk and low-risk groups.

Additional file 11: Drugs with significant differences in IC50 values between high-risk and low-risk groups.

Osimertinib is a recently approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M resistance mutations. The aim of the present meta-analysis was to investigate the efficacy and safety of osimertinib for patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Databases were searched for randomized controlled studies that reported the efficacy and safety of osimertinib versus other treatments (chemotherapy, other EGFR-TKIs, etc.) in treating EGFR-mutated NSCLC. The measured effects...

Supplementary Material 1

Additional file 10: Table S1. The sequences for all primers and siRNA.

Additional file 2: Table S2. The rumen microbiota and the presence of quorum sensing molecules.

Additional file 2: Table S2. The rumen microbiota and the presence of quorum sensing molecules.

Additional file 2: Dataset S1. The 130 unique cox1 haplotypes of Oncomelania hupensis from this study including two outgroups

Additional file 10: Supplementary Table 4. The interaction between circLRFN5 and top 120 proteins.

Additional file 10: Table S5. GO enrichment analysis by using DAVID.

Additional file 1: Table S1. The specific risk score and risk level group for each patient with ESCC.

Additional file 1.

Supplemental material, sj-xlsx-2-onc-10.1177_11795549221116834 for Concordance of Genomic Profiles in Matched Tissue and Plasma Samples From Chinese Patients With Lung Cancer by Yueming He, Weifeng Guo, Meng Xu, Junling Huang, Xiange Zhang, Huanzhang Su, Dongxia Hong and Qun Liu in Clinical Medicine Insights: Oncology

Additional file 1: Supplementary Table S1

Supplemental material, sj-rar-3-tej-10.1177_20417314221132093 for A new cell-free therapeutic strategy for liver regeneration: Human placental mesenchymal stem cell-derived extracellular vesicles by Ting Li, Yu Fu, Zeyi Guo, Honglei Zhu, Hangyu Liao, Xiaoge Niu, Lin Zhou, Shunjun Fu, Yang Li, Shao Li, Lujia Wang, Yizhou Zheng, Lei Feng, Yi Gao and Guolin He in Journal of Tissue Engineering

Additional file 4: Supplementary Table S4

Additional file 9. Table S9: Relative expression levels of 8 selected genes under four different time treatments of 12% PEG6000.

Additional file 4: Table S2. The names of the 8 cuproptosis-related lncRNAsin the model.

Additional file 5: Table S3. Theclinical features between the entire set, training set and the testing set inthe risk model.